<DOC>
	<DOCNO>NCT00309023</DOCNO>
	<brief_summary>This Phase I/II , ascend , multi-dose study BMS-663513 , agonistic anti-CD137 monoclonal antibody , administer every three week patient metastatic locally advanced solid tumor .</brief_summary>
	<brief_title>Study BMS-663513 Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) score 01 . Measurable disease . Absolute neutrophil count ( ANC ) &gt; = 1,500 cells/mm3 Platelet count &gt; = 100K cells/mm3 Hemoglobin &gt; = 9.0 g/dL Total bilirubin &lt; = 1.5 x IULN Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) alkaline phosphatase &lt; = 2.5 x institutional upper limit normal ( IULN ) Patients advance solid malignancy must melanoma , renal ovarian carcinoma History autoimmune disease . Condition require continue use systemic topical steroid use immunosuppressive agent . Active/symptomatic brain metastasis . History hepatitis B C. Concurrent malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Advanced Solid Tumors</keyword>
</DOC>